The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. While legal experts acknowledge the lack of a clear legal precedent, signs suggest that the drugmakers might find a sympathetic audience within the U.S. Supreme Court.
Eight lawsuits are winding their way through nationwide courts, with liberal and conservative judges presiding, Reuters noted.
The prospect of a legal conflict culminating in a Supreme Court review looms large.
The drugs targeted by the program represent some of the most profitable offerings in the market, encompassing medications like Bristol Myers Squibb Co's (NYSE: BMY) blood thinner Eliquis, Novartis AG's (NYSE: